No open-market selling at BlossomHill Therapeutics, Inc. in the past year, which is unusual. Instead six corporate insiders added about $25.2 million worth of BLSM.
The largest purchase came from GORDON CARL L (Director), about $10 million. That includes C-suite money, which tends to get the most attention.
Quarter by quarter: Last full quarter: net buying by insiders. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | GORDON CARL L | Director | Buy | 625,000 | $16.00 | $10.0M | SEC |
| Aug 12, 2026 | OrbiMed Capital GP VIII LLC | Director | Buy | 625,000 | $16.00 | $10.0M | SEC |
| Aug 10, 2026 | Schmid John P. | Director | Buy | 6,000 | $16.00 | $96K | SEC |
| Aug 10, 2026 | Cormorant Private Healthcare Fund VI, LP | Director | Buy | 312,500 | $16.00 | $5.0M | SEC |
| Aug 10, 2026 | Keyes Jason A | CFO | Buy | 700 | $16.00 | $11K | SEC |
| Aug 10, 2026 | Liptak Vincent Paul | Executive Officer | Buy | 2,500 | $15.80 | $40K | SEC |
| Aug 10, 2026 | Liptak Vincent Paul | Executive Officer | Buy | 2,200 | $16.00 | $35K | SEC |
In the last 12 months BlossomHill Therapeutics, Inc. insiders made open-market purchases worth about $25.2 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in BLSM was filed on 2026-08-12.
No congressional trades in BLSM were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).